o-Toluoyl Chloride CAS 933-88-0 Tolvaptan Intermediate Factory High Quality
Manufacturer Supply, High Quality, Commercial Production
Tolvaptan and Related Intermediates:
Tolvaptan CAS 150683-30-0
7-Chloro-1,2,3,4-tetrahydrobenzo[b]azepin-5-one CAS 160129-45-3
o-Toluoyl Chloride CAS 933-88-0
4-Amino-2-Methylbenzoic Acid CAS 2486-75-1
2-Methyl-4-Nitrobenzoic Acid CAS 1975-51-5
Chemical Name | o-Toluoyl Chloride |
Synonyms | 2-Methylbenzoyl Chloride |
CAS Number | 933-88-0 |
CAT Number | RF-PI396 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C8H7ClO |
Molecular Weight | 154.59 |
Melting Point | 159.5-160.9℃ |
Boiling Point | 88.0~90.0℃/12 mmHg (lit.) |
Density | 1.185 g/mL at 25℃ (lit.) |
Refractive Index | n20/D 1.5549(lit.) |
Water Solubility | Reacts with Water |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Colorless Clear Liquid |
Assay | ≥99.0% |
Benzoyl Chloride | ≤0.30% |
M&P-Methyl Benzoyl Chloride | ≤0.50% |
O-Toluic Acid | ≤0.50% |
Other Unspecified Impurity | ≤0.20% |
Total Impurities | ≤1.0% |
Loss on Drying | ≤0.50% |
Test Standard | Enterprise Standard |
Usage | Pharmaceutical Intermediates |
Package: Bottle, 25kg/Barrel or 180kg Plastic drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
o-Toluoyl Chloride (CAS 933-88-0) is used as a pharmaceutical intermediate. o-Toluoyl Chloride is used in the synthesis if quinolinone compounds as SARS CoV 3CLpro inhibitors. Also used in the synthesis of benzooxaboroles as orally active anti-inflammatory agents. o-Toluoyl Chloride is the intermediate of Tolvaptan (CAS 150683-30-0) for the treatment of hyponatremia. Tolvaptan, also known as OPC-41061, is a selective, competitive arginine vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Otsuka Pharmaceutical licensed tolvaptan under the trade name Samsca after the FDA approved the drug in May 2009.